Results 61 to 70 of about 15,487 (155)

Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children.

PLoS ONE, 2017
BackgroundThe antiretroviral drug nevirapine and the antimalarial artemisinin-based combination therapy artemether-lumefantrine are commonly co-administered to treat malaria in the context of HIV.
Liusheng Huang, Vincent Carey, Jane C Lindsey, Florence Marzan, David Gingrich, Bobbie Graham, Linda Barlow-Mosha, Phionah K Ssemambo, Portia Kamthunzi, Sharon Nachman, Sunil Parikh, Francesca T Aweeka, IMPAACT P1079 protocol team   +12 more
doaj   +1 more source

The impact of a Wastewater Treatment Works in Southern Gauteng, South Africa on efavirenz and nevirapine discharges into the aquatic environment

Emerging Contaminants, 2017
There has been growing concern regarding the pollution of the aquatic environment with synthetic organic chemicals. Antiretroviral drugs, such as efavirenz and nevirapine, are pharmaceutical drugs and are referred to as emerging contaminants.
C. Schoeman, M. Dlamini, O.J. Okonkwo
doaj   +1 more source

Nevirapine-induced side effects in pregnant women: experience of a brazilian university hospital

Brazilian Journal of Infectious Diseases
Nevirapine-based therapy is associated with increased frequency of adverse events among HIV-infected pregnant women. The aim of this article was to evaluate the incidence of adverse effects in HIV-infected women who started nevirapine during pregnancy. A
William Kondo, Elaine Aparecida Carraro, Elaine Prandel, Josiane Mourão Dias, Juliane Perini, Rodolfo Lara de Macedo, Taynah Cristina Cornelsen, Renato Sbalquiero, Maria das Graças Sasaki   +8 more
doaj   +1 more source

Immunovirological treatment out- comes after 2 years of antiretroviral therapy in children living with the human immune deficiency virus in Lagos Nigeria

Nigerian Journal of Paediatrics
Background/objective: The World Health Organization (WHO) recommends routine assessment of antiretroviral treatment outcomes to detect treatment failure early and prevent the development of drug resistance. The aim of this study was to describe treatment
Nwaiwu O, Akindele AJ, Akanmu AS, Adeyemi OO   +3 more
doaj  

Nevirapine-based regimens in HIV-infected antiretroviral-naive patients: systematic review and meta-analysis of randomized controlled trials.

PLoS ONE, 2013
BackgroundNevirapine belongs to the group of non-nucleoside reverse transcriptase inhibitors (NNRTIs) and is commonly administered in first-line treatment of HIV infection.ObjectiveSystematic review and meta-analysis was undertaken to compare ...
Paweł Kawalec, Joanna Kryst, Alicja Mikrut, Andrzej Pilc   +3 more
doaj   +1 more source

Abstracts From AIDS 2026, the 26th International AIDS Conference, 26 – 31 July 2026 Rio de Janeiro, Brazil & virtual

Journal of the International AIDS Society, Volume 29, Issue S4, July 2026.
wiley   +1 more source

Incidence and determinants of nevirapine and efavirenz-related skin rashes in West Africans: nevirapine's epitaph?

PLoS ONE, 2014
Non-nucleoside reverse transcriptase inhibitor (NNRTI) associated rash is common and frequently leads to discontinuation of NNRTIs. This study assessed the risk of developing rashes and discontinuing NNRTIs and associated factors in a large clinic in ...
Fred Stephen Sarfo, Maame Anima Sarfo, Betty Norman, Richard Phillips, David Chadwick   +4 more
doaj   +1 more source

Cost-effectiveness of childbirth strategies for prevention of mother-to-child transmission of HIV among mothers receiving nevirapine in India

Indian Journal of Community Medicine, 2010
Background: Mother-to-child transmission of HIV is an important mode of spread of HIV in India. With strategies like caesarian section and nevirapine therapy, this spread has been reduced. However, they have costs attached.
Mukherjee Kanchan
doaj  

Nevirapine [PDF]

, 2020
openaire   +1 more source

Oral Lamivudine for Extended HIV Postnatal Prophylaxis. [PDF]

Paediatr Drugs
Van de Perre P, Meda N, Tassembedo S, Moles JP, Kankasa C, Mennecier A, Mwiya M, Nagot N, Tylleskär T.   +8 more
europepmc   +1 more source